tbuckley/cabot-search huggingface dataset:
The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma
Authors: L. Tian, W. Li, J. Wang, Y. Zhang, Y. Zheng, H. Qi, X. Guo, Y. Zhang, D. Ma, H. Shen, Y. Wang
Journal: Allergy (2010)

To cite this article: Tian L, Li W, Wang J, Zhang Y, Zheng Y, Qi H, Guo X, Zhang Y, Ma D, Shen H, Wang Y. The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma. Allergy 2011; 66: 287–297. Background: Human chemokine-like factor 1 (CKLF1) is a functional ligand for human CCR4, which is highly expressed on Th2 lymphocytes and plays an important role in the pathogenesis of asthma. The expression and function of CKLF1 are associated with asthma. The CKLF1 C-terminal peptides C19 and C27 also interact with human CCR4. Albeit with weaker chemotactic activity, C19 can inhibit chemotaxis induced by both CKLF1 and CCL17. Here, we explore whether C19 can act as an antagonist in the development of asthma. Methods: A mouse model of asthma and in vitro and in vivo chemotaxis assays were used. Results: Using a mouse model of asthma, we demonstrate here that C19 reduces airway eosinophilia, lung inflammation and airway hyperresponsiveness; in contrast, C27 has little effect on these parameters. The inhibitory effects of C19 on CCR4-mediated chemotaxis could be observed in human Th2 lymphocytes and in the splenocytes from ovalbumin-sensitized mice. Furthermore, we show that C19 can inhibit CCL11-induced chemotaxis of mouse eosinophils and human CCR3-transfected or mouse Ccr3-transfected HEK293 cells. In vivo chemotaxis assays revealed that C19 and C27 can reduce CCL11-mediated recruitment of eosinophils into the peritoneal cavity and that this inhibitory effect is stronger for C19 than for C27. Conclusions: Thus, C19 can attenuate airway eosinophilia and lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma. Given its ability to inhibit human CCR3- and CCR4-meditated chemotaxis, C19 has great therapeutic potential for use in the treatment and control of allergic asthma.
Gene expression networks underlying retinoic acid–induced differentiation of acute promyelocytic leukemia cells
Authors: Ting-Xi Liu, Ji-Wang Zhang, Jiong Tao, Ruo-Bo Zhang, Qing-Hua Zhang, Chun-Jun Zhao, Jian-Hua Tong, Michel Lanotte, Samuel Waxman, Sai-Juan Chen, Mao Mao, Geng-Xi Hu, Li Zhu, Zhu Chen
Journal: Blood (2000)
404. Cloning and Expression of Canine O6-Methylguanine–DNA Methyltransferase Gene in Ex Vivo Cultured Cells
Authors: Michail M. Zaboikin, Narasimhachar Srinivasakumar, Tatiana N. Zaboikina, Friedrich G. Schuening
Journal: Molecular Therapy (2004)

The human O6-methylguanine-DNA-methyltransferase (MGMT) gene and its mutants have been used previously for in vivo selection of transduced hematopoietic stem cells with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) alone or in combination with O6-benzylguanine (BG). To allow similar in vivo selection in dogs, without the risk of inducing of an immune response, we have cloned the canine MGMT drug resistance gene (GenBank Accession No. AY423553). Comparison of canine and human MGMT coding regions indicated that there was about 62% amino acid identity and 78% similarity between the two MGMTs. The canine MGMT was also longer by 9 amino acids. Proline at position 140 and the surrounding amino acids of the human MGMT were highly conserved in the canine sequence. To determine if mutation of the proline residue at position 144 to lysine (P144K) in the canine MGMT would provide a similar advantage for selection with BG and BCNU of transduced cells as the human P140K mutant, we created the corresponding P144K mutant of canine MGMT. Bicistronic Moloney murine leukemia virus and human immunodeficiency type 1 vectors were used to express separately canine and human MGMTs in cultured canine CTAC cells. Drug-resistance assays demonstrated that the wild-type and the P144K mutant canine MGMTs provided resistance to the BCNU or BG together with BCNU selection, respectively that was comparable to the human MGMT counterparts.
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Authors: Karl Kossen, Xiaoli Qin, Sharlene Lim, Williamson Bradford, Robin Deterding, Scott Seiwert
Journal: European Respiratory Journal (2013)

Introduction:  Novel protein biomarkers of IPF may provide new insights into disease pathobiology, facilitate diagnosis, and predict disease progression.   Objective:  Broadly define the plasma protein profile of IPF and identify markers of disease activity.   Methods:  Plasma was obtained from 30 Caucasian male IPF patients and 20 demographically matched healthy volunteers. IPF samples were selected to include 15 patients that experienced significant decline in forced vital capacity over 48 weeks (median -15.2%) and 15 with a lower level of decline (median -2.7%). 1129 proteins were quantified using an aptamer-based proteomic platform (SomaLogic). Data were median normalized and differentially expressed proteins identified by Kolmogorov-Smirnov test with corrections for multiple comparisons (FDR    Results:  The plasma protein signature of IPF is markedly different from that of healthy volunteers. Consistent with previous reports, markers including MMP-7, periostin, and CCL18 are significantly increased in IPF plasma. In addition, several differentially expressed proteins correspond to mRNAs known to be differentially expressed in IPF lung tissue. Among several newly identified biomarkers are the secreted growth factors pleiotrophin and midkine. The plasma protein profile of IPF shows activation of pathways involved in immune response, cytokine signaling, cell adhesion, and apoptosis.   Conclusions:  Our results provide a broad, unbiased characterization of the plasma protein profile of IPF and define significant alterations relative to healthy individuals. Further analysis to identify markers of disease progression is underway.
A Practical Treatise on Ophthalmology.
Authors: Lawrance Webster Fox
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vaccination of adults with asthma and COPD
Authors: R. Pesek, R. Lockey
Journal: Allergy (2010)

To cite this article: Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy 2011; 66: 25–31. Vaccines play a major role in preventing potentially life-threatening diseases. More attention is now focused on the adult population, particularly as they age, as a reservoir for vaccine-preventable diseases. Adults with comorbid conditions such as asthma and chronic obstructive pulmonary disease (COPD) are considered to be at higher risk for invasive diseases, many of which are preventable through routine vaccination. This article reviews the pertinent literature for the use of vaccines in the management of adult patients with asthma and COPD.
Dominant modifier DFNM1 suppresses recessive deafness DFNB26
Authors: Saima Riazuddin, Caley M. Castelein, Zubair M. Ahmed, Anil K. Lalwani, Mary A. Mastroianni, Sadaf Naz, Tenesha N. Smith, Nikki A. Liburd, Thomas B. Friedman, Andrew J. Griffith, Sheikh Riazuddin, Edward R. Wilcox
Journal: Nature Genetics (2000)
A driver or a passenger? D421-caspase cleaved tau is associated with aggregated and insoluble tau
Authors: Yolanda Gibson, Katya Garn, Clare Hardy, Manuela Piarulli, Sarah Glover, Mark Ward, Emily McNaughton, Michael Hutton, Michael O’Neill, Joanna Wolak
Journal: Molecular Neurodegeneration (2013)

between four and eight months of age and importantly caspase-cleaved tau was shown to be associated with the insoluble fraction of tau. These changes are concomitant with progression of tau pathological changes previously observed in this model. Conclusions Caspase-cleaved tau at D421 is associated with aggregated and insoluble tau. Our findings contribute to the discussion on whether therapeutics aimed at inhibiting caspase-mediated tau cleavage could be beneficial in slowing cleavage and aggregation, and hence potentially inhibit the pathological cascade in Alzheimer’s disease.
Increased CHEK2 1100delC genotype frequency (also) in unselected breast cancer patients
Authors: M. M. De Jong, W. T. A. Van der Graaf, I. M. Nolte, G. J. Te Meerman, J. C. Oosterwijk, G. Van der Steege, M. Boezen, M. Schaapveld, J. H. Kleibeuker, E. G. E. De Vries
Journal: Journal of Clinical Oncology (2004)

9536 Background. CHEK2 was recently identified as a low-penetrance breast cancer susceptibility gene, with an increased genotype frequency of the 1100delC variant in familial cases without detectable BRCA1/2 mutations (4.2–5.5%) compared to controls (1.1–1.4%) in 2 studies. No difference in genotype frequency of the variant was observed between unselected breast cancer cases (0.3–2.0%) and controls in 3 different studies. This could be due to lack of power of the individual studies. Methods. The 1100delC variant was studied in 962 unselected breast cancer cases and 367 controls (spouses of the unselected patients) and in familial breast cancer cases with (n=75) and without (n=288) BRCA1/2 mutations. The unselected breast cancer cases were assigned to ‘high’, ‘moderate’ or ‘low’ genetic risk groups, based on age at diagnosis, bilaterality of breast cancer, number of first degree relatives with breast cancer, and co-occurrence of ovarian cancer and male breast cancer in the family. In addition, the data of the published studies and the present one were combined. Results. In unselected breast cancer patients, the variant was observed in 2.9% and in controls in 1.4% (NS). After stratifying the patients according to genetic risk, the frequency was highest in high-risk (4.4%), followed by moderate-risk (3.8%), and lowest in low-risk patients (2.4%), P-value for trend <0.05. In 288 familial cases without BRCA1/2 mutations, 6.3% carried the variant, this is higher than in controls (P-value <0.001). None of the familial cases with a BRCA1/2 mutation had the variant. The pooled analysis revealed an association with the 1100delC variant in unselected breast cancer cases (OR=2.25, P-value <0.0005) and in familial cases without BRCA1/2 mutations (OR=5.09, P-value <0.0001). Conclusion. Apart from an increased 1100delC genotype frequency in familial breast cancer cases without BRCA1/2 mutations, the genotype frequency of the CHEK2 1100delC variant increased with assumed genetic risk in unselected breast cancer cases. The pooled analysis revealed an increased 1100delC genotype frequency in unselected breast cancer cases. No significant financial relationships to disclose.
Cumulative Probability of False-Positive Recall or Biopsy Recommendation After 10 Years of Screening Mammography
Authors: Rebecca A. Hubbard, Karla Kerlikowske, Chris I. Flowers, Bonnie C. Yankaskas, Weiwei Zhu, Diana L. Miglioretti
Journal: Annals of Internal Medicine (2011)

Background
False-positive mammography results are common. Biennial screening may decrease the cumulative probability of false-positive results across many years of repeat screening but could also delay cancer diagnosis.
Summary of Informal Discussions
Authors: Theodore T. Puck
Journal: Cancer Research (1960)

nic for mammalian viruses made possible more precise quantitation of single virus particles and study of their kinetics than had before been pos sible. It also opened up possibilities of precise genetic experiments, since viruses could easily be cloned and abnormal mutants readily recognized and isolated. In our laboratory, methods for growing single cells into isolated, countable colo nies make possible the same operations for study of the host cell, with and without exposure to the virus, so providing precise and convenient means for studying viral effects on single cell morphol ogy, reproduction, biochemistry, and genetics. The discussions of Dulbecco and Rubin, among others, have demonstrated the power of these methods and the many new kinds of experimen tation which they make possible. Developments in cellular genetics and genetic biochemistry largely drawn from the simpler mi croorganisms have in the last 20 years provided us with enormously increased insight into the man ner in which genetic elements in the cells are replicated and how their informational content is transmitted to other components of the cell so as to regulate the biochemical behavior which the cell can display. The major formulations of ge netics and their biochemical concomitants which have been elucidated in recent years have been found to be applicable to every living form where they have been carefully examined. The univer sality of these genetic principles appears then to justify their application in the present problem of the role of mammalian viruses in cancer, at least as a guide for possible interpretation of experiments already carried out and for planning new attacks on these systems. The virus or virus nucleic acid as a self-replicating particle within the cell is virtually, by definition, a genetic ele ment of that particular system. Therefore, it would appear useful to examine its manifesta tions by means of the practical and conceptual tools which have been found to yield such illu minating results in studies of other self-replicat ing cellular constituents. It goes without saying, of course, that dogmatism in this field is likely to be as unfortunate as in any other field of sci ence. Thus, while studies of bacterial cell systems and bacterial viruses and their interactions fur nish us with many important models which can hardly help being extraordinarily useful in our analysis of mammalian virus and cancer action, we must be prepared to find many significant differences, at least in degree, but possibly also in kind, in the case of the multicellular animal. A number of these important differences have already been discussed in the course of this ses sion. The possibility of interaction between var ious specialized animal cells raises a whole new order of complexity in the search for an under standing of the changes introduced into such systems by viruses. Dr. Beard's beautiful experi
Treatment of patients with acquired idiopathic generalized anhidrosis
Authors: Y. Ohshima, T. Yanagishita, K. Ito, Y. Tamada, N. Nishimura, Y. Inukai, S. Iwase, J. Sugenoya, D. Watanabe
Journal: British Journal of Dermatology (2012)

Funding sources: none. Conflicts of interest: none declared. Madam, Acquired idiopathic generalized anhidrosis (AIGA) is a rare disorder in which systemic anhidrosis occurs in the absence of any causative skin, metabolic or neurological disorder.1 Treatment of AIGA almost always comprises steroid pulse therapy or high‐dose oral steroids.2–6 However, only a few previous reports have addressed courses of treatment for AIGA. We investigated the treatment of patients with AIGA who were examined at the Department of Dermatology at Aichi Medical University over the past 6 years. The subjects were 14 male patients diagnosed with and treated for AIGA during the 6‐year period from March 2005 to March 2011. The patients ranged in age from 15 to 66 years (mean, 33·1 years). A diagnosis of anhidrosis was determined using the iodine–starch test of Wada and Takagaki (Minor test) in an artificial climate room (temperature, 40 °C; humidity, 50%).7 The efficacy of steroid treatment and the recurrence of anhidrosis were also confirmed using the Minor test. Recurrence of anhidrosis was defined as a condition in which anhidrosis was observed again on the Minor test. Emotional sweating (sympathetic sweating responses to mental or physical stimuli on the palms of the hands, soles of the feet and axilla) was maintained in most patients prior to treatment. Cholinergic urticaria was present in six of the 14 patients. Histopathology of the anhidrotic areas showed no morphological abnormalities of sweat glands or sweat ducts in any patient. Slight lymphocyte infiltration was evident around sweat glands in two patients, and around sweat ducts in one. The duration from onset to treatment ranged from around 2 weeks to around 10 years (mean, 20·1 months). Sweating was seen after treatment with oral steroids alone (prednisolone, 0·5 mg kg−1 per day) in one patient, one session of steroid pulse therapy (methylprednisolone, 1000 mg per day for 3 days) in four patients, and two sessions of steroid pulse therapy in nine patients. Cholinergic urticaria was seen in six patients and disappeared after steroid pulse therapy. Anhidrosis recurred after pulse therapy in five patients, all of whom required repeated pulse therapy (Table 1). Immunosuppressants (including ciclosporin and azathioprine) were also administered to patients in whom anhidrosis recurred, but proved ineffective.
Small-diameter melanocytic lesions: morphological analysis by means of<i>in vivo</i>confocal microscopy
Authors: G. Pupelli, C. Longo, L. Veneziano, A.M. Cesinaro, G. Ferrara, S. Piana, E. Moscarella, C. Ricci, I. Zalaudek, S. Seidenari, G. Argenziano, G. Pellacani
Journal: British Journal of Dermatology (2013)

Small-diameter melanocytic lesions represent a diagnostic challenge for clinicians, as they do not follow the ABCD rule for diagnosis and do not always display reliable histopathological criteria.To analyse the confocal features of small-diameter lesions (naevi and melanomas with diameter ≤ 5 mm) to determine whether they show specific morphological criteria.Twenty-four melanomas and 72 naevi were subjected to dermoscopic and confocal evaluation along with histopathology. Significant dermoscopic and confocal differences between melanomas and naevi were evaluated by means of the Pearson χ(2) test. Odds ratios and 95% confidence intervals were calculated for each parameter. Binary logistic regression was performed to identify the reflectance confocal microscopy (RCM) independently significant features for melanoma diagnosis.The seven-point checklist dermoscopic score was ≥ 3 in 22 melanomas and in 33 naevi. The combination of cells' pleomorphism and architectural disorder (i.e. nonspecific pattern or irregular junctional nests upon confocal examination) are the most striking criteria for consistent diagnosis of small melanoma. The presence of atypical cells, more than five atypical cells per mm(2) , and roundish atypical cells at the dermoepidermal junction showed the highest odds ratios. From logistic regression, the presence of at least five pagetoid cells per mm(2) , tangled lines within the epidermis, and atypical roundish cells at the dermoepidermal junction resulted in the three independent confocal parameters that characterized small melanomas.Small melanomas frequently reveal specific dermoscopic and confocal features. Moreover, the combination of dermoscopy and RCM can lead to a correct diagnosis of a number of naevi that share some morphological aspects with melanomas.
Managing demand: A patient led NHS: managing demand at the interface between lay and primary care
Authors: A. Rogers, V. Entwistle, D. Pencheon
Journal: BMJ (1998)

This is the second of five articles on ways of managing demand for health care

People currently deal with many, if not most, health problems without consulting the health service. Relatively small decreases in these self care behaviours or increases in the accessibility of services could produce large changes in demand for formal care. We believe that scope exists for the health service actively to promote self care and improve the way it responds to people's illnesses so that needs are met efficiently in appropriate and acceptable ways. This may mean both encouraging demand for some forms of care — for example, for problems where early intervention is desirable and promoting self care for other problems. We examine particularly how the NHS should support self care as a way of managing the demand for formal health care.

#### Summary points

Knowledge, culture, attitudes, experience, and healthcare organisation are the key determinants of when, why, and how people access formal health care.

To ensure the most appropriate demand on the health service, the NHS needs to encourage some demand and promote alternative ways of managing other demand.

This can be done by building on the ways in which people already take responsibility for managing their health and illness

Information that is relevant, accessible, meaningful, and integrated with other formal care is important

So is a culture in which risk, responsibility, control, and uncertainties can be discussed and shared between providers, funders and users

More graduated access to the system should be offered, through a single point of entry-triage

Informal and self care constitute an important but often hidden aspect of the supply of health care. Ordinary people are providers of care. They have experience of caring for themselves and others and regularly provide advice about, and take responsibility for, matters of health and illness. …
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
Authors: Harriet L. Robinson, David C. Montefiori, R. Paul Johnson, Kelledy H. Manson, Marcia L. Kalish, Jeffrey D. Lifson, Tahir A. Rizvi, Shan Lu, Shiu-Lok Hu, Gail P. Mazzara, Dennis L. Panicali, James G. Herndon, Rhona Glickman, Maria A. Candido, Shari L. Lydy, Michael S. Wyand, Harold M. McClure
Journal: Nature Medicine (1999)
Abstract 17331: Active Role of Supporting Cells and Heterotypic Interactions with Endothelial Cells in 3 Dimensional Clusters Guide in vitro Angiogenesis
Authors: Russell Witt, Limin Wang, Claus Sondergaard, Tracy Clift, Ming-Sing Si
Journal: Circulation (2012)

Introduction: Current methods of creating microvasculature in engineered tissue rely on the angiogenic properties of endothelial cells (ECs) and supporting cells (SCs), but yield a sparse network. ...
Trusts are ill prepared for 58 hour week for junior doctors
Authors: Katherine Burke
Journal: BMJ (2004)

Trusts may be ill prepared for new limits on junior doctors' working hours because of a lack of government support and confusion over the legislative details, a parliamentary inquiry has heard.

Doctors' leaders have informed the House of Lords inquiry that national guidance has failed to materialise on how trusts can cut junior doctors' weekly hours to 58—just months away from the deadline.

From August 2004 the European Working Time Directive will be extended to include junior doctors. The cut in hours is equivalent to about a 10% drop in the total hours worked by such trainees. But the BMA has told the inquiry that the working time directive pilots taking place throughout England …